[HTML][HTML] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
[HTML][HTML] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
[HTML][HTML] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in immunology, 2022 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - europepmc.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
[引用][C] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - 2022 - europepmc.org
1 Background Liver cancer is currently the fourth most likely cause of cancer death (1) Risk
factors for HCC include hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection …
factors for HCC include hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection …